Management of High Ostomy Output

Introduction to Octreotide

The American Gastroenterological Association recommends subcutaneous octreotide (50 mcg twice daily) over intravenous administration for slowing high ostomy output, as it is equally effective, less invasive, and supported by clinical guidelines 1
Octreotide effectively reduces ileostomy diarrhea and large volume jejunostomy output through several mechanisms, including reducing intestinal secretions, decreasing volume of parenteral supplements needed, and reducing sodium output in parallel with fluid reduction, and maintains effectiveness in long-term use 1

The initial dose of subcutaneous octreotide is 50 mcg twice daily, administered before meals as intestinal output rises after eating 1
The duration of treatment may be short-term (especially during first 6 months after surgery) or long-term based on clinical response 2
Regular assessment of stoma output volume and electrolytes is essential for monitoring 3

Octreotide is most beneficial for patients with high-output ostomies (>2 L/day) 2
Patients with net secretory output also benefit from octreotide treatment 1
Those in whom fluid and electrolyte management remains problematic despite conventional treatments may also benefit from octreotide 2

Daily monitoring of stoma output volume, weight, urine output, and serum electrolytes is recommended, as well as assessing for signs of dehydration and potential fluid retention when initiating treatment 2, 3
Octreotide may reduce fat absorption in some patients, but does not significantly change total energy or nitrogen absorption, and requires careful monitoring to prevent fluid retention when initiating treatment 1, 2

First-line measures include restricting oral hypotonic fluids to <500 ml/day, providing glucose-saline solution with sodium concentration ≥90 mmol/L, and adding antimotility agents (loperamide 4-8 mg, up to 24 mg at a time) 1, 3
Second-line measures include adding acid-reducing medications (H2 antagonists or proton pump inhibitors) and subcutaneous octreotide 50 mcg twice daily 1, 2
Third-line measures include considering intravenous or subcutaneous saline supplementation and evaluating the need for parenteral nutrition 1

Failing to restrict oral hypotonic fluids is a critical mistake, as well as using standard anti-diarrheal dosing instead of higher doses often needed, not recognizing underlying causes of high output, encouraging excessive water intake, and inadequate sodium replacement 3